GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Laboratories Ltd (NSE:INDSWFTLAB) » Definitions » Gross Profit

Ind-Swift Laboratories (NSE:INDSWFTLAB) Gross Profit : ₹4,560 Mil (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Ind-Swift Laboratories Gross Profit?

Ind-Swift Laboratories's gross profit for the three months ended in Dec. 2023 was ₹1,321 Mil. Ind-Swift Laboratories's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was ₹4,560 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Ind-Swift Laboratories's gross profit for the three months ended in Dec. 2023 was ₹1,321 Mil. Ind-Swift Laboratories's Revenue for the three months ended in Dec. 2023 was ₹2,875 Mil. Therefore, Ind-Swift Laboratories's Gross Margin % for the quarter that ended in Dec. 2023 was 45.94%.

Ind-Swift Laboratories had a gross margin of 45.94% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Ind-Swift Laboratories was 42.08%. The lowest was 16.23%. And the median was 37.65%.


Ind-Swift Laboratories Gross Profit Historical Data

The historical data trend for Ind-Swift Laboratories's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift Laboratories Gross Profit Chart

Ind-Swift Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,827.25 3,099.96 3,751.05 4,096.13 4,404.47

Ind-Swift Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,300.97 305.59 1,480.76 1,452.60 1,320.79

Competitive Comparison of Ind-Swift Laboratories's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ind-Swift Laboratories's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's Gross Profit distribution charts can be found below:

* The bar in red indicates where Ind-Swift Laboratories's Gross Profit falls into.



Ind-Swift Laboratories Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Ind-Swift Laboratories's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )=Revenue - Cost of Goods Sold
=12073.1 - 7668.63
=4,404

Ind-Swift Laboratories's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=2875.143 - 1554.353
=1,321

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,560 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Ind-Swift Laboratories's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=1,321 / 2875.143
=45.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Ind-Swift Laboratories  (NSE:INDSWFTLAB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Ind-Swift Laboratories had a gross margin of 45.94% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Ind-Swift Laboratories Gross Profit Related Terms

Thank you for viewing the detailed overview of Ind-Swift Laboratories's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Ind-Swift Laboratories (NSE:INDSWFTLAB) Business Description

Traded in Other Exchanges
Address
SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh, PB, IND, 160 101
Ind-Swift Laboratories Ltd is engaged in the business of active pharmaceutical ingredients (API). The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. Geographically, it derives a majority of revenue from Outside India.

Ind-Swift Laboratories (NSE:INDSWFTLAB) Headlines

No Headlines